TY - JOUR T1 - A Phase II Study of Gemcitabine at Fixed Infusion Rate of 10 mg/m<sup>2</sup>/min with or without Immunotherapy in Advanced Renal Cancer JF - Anticancer Research JO - Anticancer Res SP - 4461 LP - 4464 VL - 27 IS - 6C AU - FABLE ZUSTOVICH AU - GIUSEPPE CARTEI AU - DAVIDE PASTORELLI AU - ORNELLA NICOLETTO AU - FEDRA GOTTARDO AU - LUCA DE ZORZI AU - MASSIMO DAL BIANCO Y1 - 2007/11/01 UR - http://ar.iiarjournals.org/content/27/6C/4461.abstract N2 - Background: Advanced renal cancer remains a challenge for oncologists since no treatment other than surgery has demonstrated a clear survival advantage. Patients and Methods: Gemcitabine was given to suitable patients at a fixed infusion rate of 10 mg/m2/min. Eighteen patients received concomitant immunotherapy, mostly low doses of interleukin 2 (IL2). Results: Thirty patients were enrolled. The overall response rate was 14% (22% in the subset of patients treated with both chemotherapy and immunotherapy) with a median progression-free survival time of 4.1+ months. Toxicity was not mild, mostly fatigue, nausea and anaemia, even though not life threatening. Conclusion: Gemcitabine at the fixed infusion rate of 10 mg/m2/min with concomitant low doses of IL2 could be useful in the palliative treatment of symptomatic patients with renal carcinoma progressing after tyrosine kinases inhibitor. Copyright© 2007 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved ER -